Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure

JAMA

Volumn 305, Issue 20, 2011, Pages 2088-2095

  Alehagen, Urban ^a,b   Dahlström, Ulf ^a,b   Rehfeld, Jens F ^c   Goetze, Jens P ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b County Council of Östergötland   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; COPEPTIN; HEMOGLOBIN; UNCLASSIFIED DRUG; VASOPRESSIN;

AGE; AGED; ARTICLE; CAUSE OF DEATH; CLINICAL CLASSIFICATION; CLINICAL EXAMINATION; COHORT ANALYSIS; DIABETES MELLITUS; DOPPLER ECHOCARDIOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW YORK HEART ASSOCIATION FUNCTIONAL CLASS III; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL RATE; SYMPTOM;

EID: 79957521352     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.666     Document Type: Article

References (28)

1. Apple FS, Trinity E, Steen J, Prawer S, Wu AH. BNP test utilization for CHF in community hospital practice. Clin Chim Acta. 2003;328(1-2):191-193. (Pubitemid 36135797)
2. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106(4):416-422. (Pubitemid 34803684)
3. Alehagen U, Lindstedt G, Eriksson H, Dahlström U. Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Clin Chem. 2003;49(8):1337-1346. (Pubitemid 36900620)
4. Gegenhuber A, Mueller T, Firlinger F, Lenz K, Poelz W, Haltmayer M. Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Clin Chem. 2004;50(2):454-456. (Pubitemid 38156394)
5. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. 2005;95(9A):8B-13B.
6. Nakamura T, Funayama H, Yoshimura A, et al. Possible vascular role of increased plasma arginine vaso-pressin in congestive heart failure. Int J Cardiol. 2006; 106(2):191-195. (Pubitemid 41728937)
7. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55(19):2096-2106.
8. Voors AA, von Haehling S, Anker SD, et al; OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30(10):1187-1194.
9. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115(16):2103-2110. (Pubitemid 46659061)
10. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350(9081):829-833. (Pubitemid 27404343)
11. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J. 1999;20(6):447-455. (Pubitemid 29116541)
12. Jochberger S, Dörler J, Luckner G, et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med. 2009;37(2):476-482.
13. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55(19):2906-2106.
14. Dieplinger B, Gegenhuber A, Holtmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart. 2009;95(18):1508-1513.
15. Alehagen U, Eriksson H, Nylander E, Dahlström U. Heart failure in the elderly: characteristics of a Swedish primary health care population. HeartDrug. 2002;2:211-220. (Pubitemid 36091865)
16. Swedberg K, Pfeffer M, Granger C, et al; Charm- Programme Investigators. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail. 1999;5(3):276-282. (Pubitemid 29449267)
17. Moyé LA, Pfeffer MA, Braunwald E; SAVE Investigators. Rationale, design and baseline characteristics of the survival and ventricular enlargement trial. Am J Cardiol. 1991;68(14):70D-79D.
18. Choy AM, Darbar D, Lang CC, et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. Br Heart J. 1994;72(1):16-22. (Pubitemid 24245380)
19. Jensen-Urstad K, Bouvier F, Höjer J, et al. Comparison of different echocardiographic methods with radionuclide imaging formeasuring left ventricular ejection fraction during acute myocardial infarction treated by thrombolytic therapy. Am J Cardiol. 1998;81(5):538-544. (Pubitemid 28182414)
20. van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol. 1996;77(10):843-850. (Pubitemid 26143494)
21. Mebazaa A, Nieminen MS, Packer M, et al; SURVIVE Investigators. Levosimendan vs dobutamine for patientswith acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297(17):1883-1891.
22. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-119. (Pubitemid 43032474)
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.
24. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52(4):266-272. (Pubitemid 351957847)
25. Ebert TJ, Cowley AW Jr, Skelton M. Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest. 1986;77(4):1136-1142. (Pubitemid 16047132)
26. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol. 1985;248(3, pt 2):H396-H402. (Pubitemid 15106953)
27. Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999;195(1-2):93-98. (Pubitemid 29259773)
28. Fan YH, Zhao LY, Zheng QS, Dong H, Wang HC, Yang XD. Arginine vasopressin increases iNOS-NO system activity in cardiac fibroblasts through NF-kappaB activation and its relation with myocardial fibrosis. Life Sci. 2007;81(4):327-335. (Pubitemid 47030575)